Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Intercept Pharmaceuticals Inc patents


Recent patent applications related to Intercept Pharmaceuticals Inc. Intercept Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Intercept Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Intercept Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Intercept Pharmaceuticals Inc-related inventors


Pharmaceutical compositions for combination therapy

The present application relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a fxr mediated disease or condition, such as nafld and nash, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.. ... Intercept Pharmaceuticals Inc

Methods for modulating bone density

. . The present invention relates to methods of treating, reducing the risk of, preventing, or alleviating a symptom of a disease or condition associated with changes in bone density, osteoporosis, or an osteopenic disease, or inducing osteogenesis or bone growth, or slowing, preventing, or reversing the reduction in bone density in a subject in need of treatment thereof, comprising administering a compound of the invention to the subject.. . ... Intercept Pharmaceuticals Inc

Pharmaceutical compositions for combination therapy

. . The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e.g., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (pbc), primary sclerosing cholangitis (psc), portal hypertension, bile acid diarrhea, nafld (nonalcoholic fatty liver disease), nash (non-alcohol-induced steatohepatitis), and other chronic liver diseases. ... Intercept Pharmaceuticals Inc

Treatment of fibrosis using fxr ligands

. . . . . . . . The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid x receptor (fxr) is expressed. This method involves the step of administering a high potency, activating ligand of fxr in an effective amount to a patient who is not suffering from a cholestatic condition. ... Intercept Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Intercept Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Intercept Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###